Tylenol maker Kenvue misses sales estimates amid Kimberly-Clark's $48.7-billion deal

Core Insights - Kenvue missed Wall Street estimates for third-quarter sales, reporting net sales of $3.76 billion, below the expected $3.84 billion [4] - The company announced its acquisition by Kimberly-Clark for approximately $48.7 billion, leading to a 20% increase in its shares during premarket trading [1] - Kenvue's self-care segment, which includes brands like Tylenol, experienced a 3.8% decline in sales to $1.56 billion [3] Financial Performance - Kenvue's third-quarter net sales decreased by 3.5% compared to the previous year [4] - The adjusted profit was reported at 28 cents per share, slightly above the estimate of 27 cents [4] - The company reiterated its 2025 adjusted profit outlook of between $1.00 and $1.05 per share, with expectations of low-single-digit declines in net sales for that year [5] Management Changes - Kenvue appointed Kirk Perry as its permanent CEO, along with two other executives from Procter & Gamble and Mondelēz International [4] - The leadership change follows increased investor pressure due to weaknesses in Kenvue's core businesses, particularly in skin health and beauty [3]